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Abstract  
The association between obstructive sleep apnea syndrome (OSAS) and 
glucose intolerance has been reported in previous study. However, the 
effects of prosthetic mandibular advancement (PMA) on blood glucose 
levels and insulin resistance remain unclear. The objective of this study was 
to investigate the short-term effects of PMA on glycemic control in type 2 
diabetes mellitus (T2DM) patients with OSAS. Thirty-four T2DM patients 
were diagnosed with OSAS based on a two-channel (airflow and SpO2) 
portable sleep apnea monitor. These patients were divided into two groups: 
18 patients who underwent PMA (Group 1) and 16 patients who were unable 
to undergo PMA (Group 2). In Group 1, a significant difference was 
observed in the respiratory disturbance index  obtained before and after 
using the PMA (baseline, 17.7 ± 9.8; with PMA, 8.3 ± 7.7, p<0.001). The 
usage of the PMA caused significant improvements of the changes in fasting 
blood sugar levels after two days and HbA1c levels from those of the 
baseline levels after one month and three months from those of the baseline 
levels (baseline, 8.3±1.4%; after one month, 7.6±1.2%;  after three months, 
7.3±1.1%,respectively, p<0.05). Our results suggest that PMA may have an 
effect on glycemic control in T2DM patients with OSAS.  
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Introduction 
Obstructive sleep apnea (OSA) is a common disorder characterized by 
repetitive cessation of breathing during sleep with daytime consequences, 
including subjective daytime sleepiness, and impaired cognitive function 
and memory. Approximately 3%–19% adult males and 1.2%–15% adult 
females in the general population suffer from OSA defined by an apnea–
hypopnea index (AHI) of ≥5 and daytime hypersomnolence 1-4).  
The association between OSA and glucose intolerance has been reported 
previously 5 -8), and a previous study estimated that the prevalence of OSA in 
patients with type 2 diabetes mellitus (T2DM) was 86.3% 9). Previous 
reports have also shown a relationship between OSA and obesity. Moreover, 
OSA is reported to be independently associated with metabolic syndrome, 
hypertension, insulin resistance, impaired glucose tolerance, and 
dyslipidemia  5 ,10 ,11 ). Therefore, it is essential to recommend OSA patients to 
receive suitable therapies to treat the abovementioned conditions when 
present. Nasal continuous positive airway pressure (CPAP) therapy has been 
globally accepted as the first -line therapy for T2DM with OSA 5,12-14). 
However, Grimaldi et al. emphasized the necessity to prolong the CPAP 
duration to at least 6 to 7 h per night in order to cover maximum rapid eye 
movement (REM) sleep 15). Although prosthetic mandibular advancement 
(PMA) therapy is less effective than CPAP, it may alleviate disordered 
breathing during REM sleep if used throughout the night . 
During the last two decades,  PMA therapy has also been shown to be 
effective against OSA  16). PMA therapy causes the mandible to protrude 
forward, thus preventing or minimizing upper airway collapse during sleep. 
5 
 
It prevents sleep apnea, which induces hypoxia  17-19). The largest 
randomized controlled trial of CPAP vs. PMA therapies showed that CPAP 
therapy was more efficacious than PMA therapy in decreasing AHI, 
although the compliance rate was higher with PMA therapy 20). Therefore, 
the comfort of patients with OSA who consent to undergo treatment should 
not be neglected 16). 
Although the effects of OSA treatment with CPAP on glycemic control 
have been mostly reported  5 ,12-14), those of OSA treatment with PMA have 
not. The aim of this study was to evaluate the short-term effects of PMA 
therapy on glycemic control in T2DM patients with OSA by measuring and 
comparing fasting blood sugar (FBS) and hemoglobin A1c (HbA1c) levels  
before and after PMA therapy. 
 
Materials and Methods 
Participants 
Between August 2010 and April 2013, we evaluated 483 inpatients 
undergoing treatment for T2DM who attended a diabetes mellitus education 
program in the Department of Endocrinology and Diabetes Mellitus, 
Fukuoka University Hospital, Japan. Of the total, 74 inpatients who gave 
their consent to participate in the  study underwent assessment of  the degree 
of sleep apnea using a two-channel (airflow caught by only a nasal pressure 
transducer and SpO2) portable sleep apnea monitor (LS-120/120S, Fukuda 
Denshi Co., Ltd., Tokyo, Japan) in the hospital ward. Patients with 
cerebrovascular, neurological, or chronic respiratory diseases were 
excluded. Of the 74 patients, 28 patients had AHI <  5 according to an 
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overnight apnea monitoring experiment. The remaining 46 patients had AHI 
≥ 5 and were diagnosed with OSA. Of these 46 patients,  12 discontinued 
PMA therapy within 3 months because of stomatitis (n = 4), lack of 
improvement (n =1), and unclear reasons (n = 7). Eventually, 34 inpatients 
(19 males and 15 females; mean age, 64.8 ± 9.7 years) with T2DM were 
enrolled in this study (Table 1). The study was approved by the ethics 
committee of the Fukuoka University Hospital , and informed consent was 
obtained from all patients.  Obstructive apnea was defined as the absence of 
or a minimum least 90% decrease in nasal airflow for at least 10 s 
accompanied by continued or increased in respiratory effort. Hypopnea was 
defined as a minimum 30% decrease in nasal airflow for at least 10 s 
accompanied by a minimum 4% decrease in oxygen saturation. AHI was 
calculated as the total number of apneas and hypopnea  events divided by the 
total recording time in hours . 
The participants were divided into two groups: Group 1, including 18 
patients who underwent PMA therapy (5 ≤ AHI < 15) and/or were unable to 
accept CPAP therapy despite a moderate AHI of ≥ 15, and Group 2, 
including 16 patients who did not undergo PMA therapy (5 ≤ AHI < 30; Fig. 
1). The reasons why the Group 2 patients could not undergo PMA therapy 
included refusal to wear the devise in  9 patients, requirement of dental 
treatment before PMA therapy in 7, and the presence of moderate or severe 
OSA (AHI of ≥15) requiring CPAP therapy in 2. All patients were 
hospitalized for T2DM treatment and were  attending a diabetes mellitus 
education program; therefore, the 9 patients who refused to wear the PMA 
devise may not have felt the need for OSA treatment. These patients  did not 
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receive any other OSA treatment.  
 
Type of PMA and titration 
All PMA devices were fabricated by the same dentist. The device used in 
this study was fabricated using heat-cured acrylic polymer.   
To wear a PMA device, patients are required to have at least 10 maxillary 
and 10 mandibular teeth. The patients in Group 1 had a sufficient number of 
teeth to help in retention of the PMA device, with the ability to protrude the 
mandible forward by ≥6 mm, i.e., up to 70% of the maximum mandibular 
advancement. They wore the PMA device for approximately 1 week after 
hospitalization when they completed the first stage of the diabetes mellitus 
education program. Their antiglycemic therapy remained constant during 
the study period. The amount of mandibular advancement was adjusted by 
evaluating changes in the upper and lower pharyngeal airway spaces during 
mandibular advancement using cephalometry and fiberoptic endoscopy. 
 
Examination and assessment  
In Group 1, AHI was measured before and 2 days after PMA therapy. FBS, 
blood pressure, and low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels 
were measured before, 2 days after, and 1 and 3 months after PMA therapy. 
In addition, HbA1c levels were measured before and after 1 and 3 months 
after PMA therapy. In Group 2, the same clinical parameters were evaluated 
on the day of hospitalization and 1 and 3 months after hospitalization. 
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Statistical analysis 
Differences in patient characteristics  and sleep apnea monitor findings 
which exhibited a normal distribution, were compared between the two 
groups using the unpaired t-test, and the chi-squared test, while the other 
datasets compared using the Mann-Whitney U test. Differences in sleep 
apnea monitor findings before and after PMA therapy were compared using 
the paired t-test. Two-way repeated measures ANOVA with post-hoc tests 
was used to compare FBS and HbA1c levels  at baseline with those at 2 days  
(only FBS levels),  1 month, and 3 months after PMA therapy. A  P-value of 
<0.05 was considered statistically significant. All statistical analyses were 
performed using the SPSS statistical software package (version 12.0J; SPSS 
Inc., Chicago, IL, USA). 
 
Results 
There was no significant difference in the characteristics of patients at 
baseline and in the apnea monitor findings between the two groups (Table 1, 
2). Uninterpretable data, such as those obtained when the participants woke 
up to use the washroom or other activities,  in the sleep studies was excluded 
from analysis (Group 1, 87.5 ± 31.4 min; Group 2, 94.1 ± 32.3 min). 
 No participants in Group 1 complained of jaw discomfort. From the 
patients’ medical records, no differences were observed in food and caloric 
intake between before and after PMA therapy.  The patients wore the PMA 
device during bed time (at least ≥5 h) for 3 months. In Group 1, a 
significant difference was observed between AHI at baseline and that after 
PMA therapy (baseline, 17.7 ± 9.8; after PMA, 8.3 ± 7.7, p < 0.001; Table 
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3). There was a significant increase in the minimum oxyhemoglobin 
saturation from 79.8 ± 6.0% to 85.7 ± 4.5% after using the PMA (p < 0.001) 
and the mean oxyhemoglobin saturation from 94.6 ± 1.8% to 95.9 ± 1.8% (p 
= 0.03) after PMA therapy. With regard to apnea, hypopnea, and  4% oxygen 
desaturation episodes, significant differences were observed between values 
at baseline and those after PMA thrapy. 
A significant decrease was observed between FBS levels at baseline and 
those at 2 days after PMA therapy (152.1 ± 39.9 mg/dL vs. 133.6 ± 30.7 
mg/dL; p = 0.015: Fig.1). HbA1c levels were also significantly different at 
baseline and at 1 and 3 months after PMA therapy (baseline, 8.3 ± 1.4%; at 
1 month, 7.6 ± 1.2%; and at 3 months; 7.3 ± 1.1%, respectively, with p = 
0.01 and after three months; p = 0.012, respectively; Fig.2). Although no 
significant differences were observed between the two groups (FBS, p = 
0.145; HbA1c, p = 0.708), Group1 showed a greater improvement in FBS 
and HbA1c levels compared with Group2. There was no significant 
difference between blood pressure, LDL-C levels, HDL-C levels, and TG 
levels at baseline and those at 1 month after PMA therapy. 
Each group showed a significant differences between the body mass index 
(BMI) on the day of hospitalization and at 3 months after hospitalization  
(Group 1, 27.1 ± 5.3 vs. 25.7 ± 4.6, p=0.007; Group 2, 25.8 ± 3.7 vs. 
24.9 ± 3.2, p=0.002). However, there was no significant difference in the 
rate of change in BMI between the two groups (p = 0.35). 
 
Discussion 
OSA is characterized by repetitive episodes of upper airway obstruction 
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occurring during sleep, generally in association with a decrease in blood 
oxygen saturation  19).  Previous studies have shown that OSA is associated 
with insulin resistance and T2DM 5,6,10,22 -26). In this study, we assessed the 
short-term effects of PMA therapy on glycemic control in T2DM patients 
with OSA. 
To the best of our knowledge, this study is the first to evaluate the impact 
of PMA therapy on glycemic control in patients with OSA. Improvement of 
intermittent hypoxemia by the use of a PMA device during sleep indicated a 
beneficial effect on glycemic control in this study. It appears that any 
significant improvement in AHI and oxygen saturation levels associated 
with PMA therapy may have an immediate effect on blood glucose levels in 
T2DM patients. In this study, FBS levels decreased in only 2 days, while 
HbA1c levels also decreased in a month’s time. These short-term changes 
decreased the influence of possible confounding factors such as insulin and 
diet therapy and suggested the immediate effects of PMA therapy on not 
only OSA but also glycemic control. With regard to change in FBS levels, 
the absence of a significant  improvement at 1 month after PMA therapy may 
have been caused by changes in the patient’s diet during and after 
hospitalization. Although it is important to maintain compliance with T2DM 
treatment, a convenient therapeutic option such as PMA therapy is 
meaningful for T2DM patients with OSA. 
Previous studies showed that the association of insulin resistance with age,  
BMI, and the 4% oxygen desaturation index and concluded that the most 
reliable predictor of insulin resistance was the 4% oxygen desaturation 
index, not BMI 23). Furthermore, it has been reported that the severity of 
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OSA is associated with the degree of insulin resistance, and that 
intermittent hypoxemia caused by recurrent apnea and hypopnea is likely to 
be an important intermediate factor in the causal pathway 12). 
Tamura et al. listed some intermediate factors in the causal pathway 
between OSA and impaired glucose metabolism, includ ing the activation of 
the sympathetic nervous system, sleep loss and sleep deprivation, recurrent 
intermittent hypoxemia, and obesity 22). Many studies have investigated and 
mentioned recurrent intermittent hypoxemia as one of the intermediate 
factors 27-33). One of these studies concluded that the most reliable predictor 
of insulin resistance was the 4% oxygen desaturation index , not BMI 6). 
Sulit et al. reported that the strongest index associated with impaired 
glucose tolerance was the time spent at an oxygen saturation of <90%  34). In 
our study, the 4% oxygen desaturation index decreased from14.0 ± 8.6 at 
baseline to 8.6 ± 7.8 after PMA therapy (p = 0.002; Table 3). The decreases 
in FBS and HbA1c levels in our patients may have been caused by an 
improvement in intermittent hypoxemia.  To evaluate insulin resistance,  we 
measured serum C-peptide levels instead of HOMA-IR in five patients in 
this study because the latter may be influenced by insulin therapy. In four of 
the five patients, the serum C-peptide level decreased 2 days after PMA 
therapy compared with that at baseline (baseline, 3.3 ± 1.1%; after 2 days, 
2.5 ± 1.6%; after three months, 2.4 ± 0.8%). Although there is a need for 
further data, these findings suggest a possibility that PMA therapy improves 
insulin resistance in T2DM patients with OSA. Unfortunately, our results 
did not provide any information about sleep loss and sleep deprivation 
because we did not analyze sleep problems using a complete 
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polysomnography examination. There was no significant difference in the 
improvement of FBS and HbA1c levels between the obese and nonobese 
patients. This finding may support the hypothesis that oxygen desaturation 
is a more reliable predictor of insulin resistance compared with BMI. 
 On the other hand, evidence on the effects of CPAP therapy on insulin 
resistance has been inconsistent  25). Previous studies reported that CPAP 
therapy did not significantly change HbA1c levels in patients with impaired 
glucose tolerance or T2DM 23). Babu et al. studied changes in interstitial 
glucose levels and measured HbA1c levels in 25 T2DM patients before and 
after CPAP therapy for OSA 12).  After CPAP therapy, they found a 
significant decrease in both 1-h postprandial glucose levels (baseline, 
148 ± 200 mg/dL; after CPAP therapy, 83 ± 117 mg/dL, p = 0.003) and 
HbA1c levels (baseline, 9.2 ± 2.0%; after CPAP therapy, 8.6 ± 1.8%; p = 
0.02). Furthermore, they showed a significant correlation between the 
decrease in HbA1c levels and the duration of CPAP therapy, indicating the 
importance of device compliance for metabolic improvements after CPAP 
therapy. 
PMA therapy prevents upper airway collapse in patients with OSA. A 
recent guideline by the American Academy of Sleep Medicine concluded 
that oral appliances are less effective than CPAP therapy, although they are 
a reasonable alternative for select patients with mild to moderate OSA  35).  
Both our study, which involved PMA therapy, and the study by Babu  et al. 
12), which involved CPAP therapy, showed a decrease in FBS ( 12% and 44%, 
respectively) and HbA1c levels (7% and 12%, respectively) indicating that 
the effects of PMA therapy on glycemic control are comparable to those of 
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CPAP therapy in OSA patients with T2DM. Although Babu et al. 
emphasized the importance of compliance with CPAP therapy  12), most OSA 
patients also exhibit good compliance with PMA therapy because they use 
the PMA device while sleeping 12). Grimaldi et al. suggested that 4 h of 
CPAP use left 60% of REM sleep untreated, leading to insufficient 
improvements in HbA1c levels 15). PMA therapy may be used for a longer 
duration than CPAP during sleep, thus covering more of the REM sleep 
cycle and resulting in better glycemic control . 
The duration of T2DM in our patients was over 10 years (Group 1, 
12.8 ± 12.3 years; Group 2, 11.0 ± 10.0 years; Table 1); however, the 
duration of OSA influence on their blood glucose levels and insulin 
resistance remains unclear. Considering the mean age of our patients 
(Group 1, 64.7 ± 10.8 years; Group 2, 64.9 ± 8.6 years; Table 1) and the 
mean AHI (Group 1, 17.7 ± 9.8 /h; Group 2, 16.9 ± 13.0 /h; Table 2), most 
participants may have developed the initial symptoms of OSA at least 
midway during the course of T2DM. T2DM in our patients was considered 
to be complicated by OSA for certain periods of time.  
This study has some limitations. First, although the results of clinical 
examination are influenced by factors other than PMA therapy, such as 
insulin and diet therapy for T2DM or patient adherence to treatment, we 
only assessed the short-term effects of PMA therapy during hospitalization 
and at 1 and 3 months after PMA therapy. Despite this, FBS levels at 2 days 
and HbA1c levels at 3 months (which reflects mean glycemia levels for the 
previous 3 months) after PMA therapy were considered to be influenced 
mainly by PMA therapy. To evaluate the long-term effects of PMA therapy 
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on glycemic control, further adjustment of confounding factors is needed.  
Second, because we used a two-channel (airflow and SpO2) portable sleep 
apnea monitor to assess the effects of PMA therapy, the mechanism by 
which PMA therapy affected sleep disorders remains unclear. We excluded 
patients with cerebral vascular or neuromuscular disorders  from the study, 
not patients with central apneas perfectly. A complete polysomnography 
examination is required to explain the relationship between improvements 
in glycemic control and sleep problems.  
 
Conclusion 
Although there was no significant difference between patients who did and 
did not undergo PMA therapy in this study, the former showed a significant 
improvement in FBS and HbA1c levels after PMA therapy. Although the 
requirement for further controlled trials with a larger sample size and 
complete polysomnography examinations are required, the results of this 
study suggest that PMA therapy may improve glycemic control in T2DM 
patients with OSA.  
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Figure legends  
Fig. 1, Change of fasting blood sugar (FBS)  
There was a significant difference in only Group 1  between baseline and 
after two days using the PMA. 
Fig. 2, Change of hemoglobin A1c (HbA1c) (NGSP)  
There were significant differences in only Group 1 between baseline and 
after one month, between baseline and after three months using the PMA.  
Table 1. Patient characteristics at baseline 
Group 1
(n=18)
Group 2
(n=16)
p
Age (year) 64.7±10.8 64.9±8.6 0.95
Male sex 50.0% 37.5% 0.35
Body mass index (kg/m2) 27.1±5.3 25.8±3.7 0.42
Waist circumference (cm) 100.7±14.9 105.0±14.5 0.60
Epworth Sleepiness Scale score 5.9±3.6 5.1±3.8 0.55
Brinkman index 624.4±854.5 548.8±653.9 0.78
Alcohol (U/week) 7.6±10.8 14.3±21.6 0.26
Medications for
diabetes mellitus 
・Insulin+OHA 27.7% 50.0%
0.46
・Insulin (U) 33.3%
(10.8±11.9)
18.8%
(11.9±14.8)
・OHA 22.2% 25.0%
・Dietetic treatment only 17.7% 6.2%
Duration of Medications for diabetes mellitus (year) 12.8±12.3 11.0±10.0 0.65
Hypertension 66.7% 62.5% 0.54
Hyperlipidemia 50.0% 50.0% 1.0
Blood pressure (mmHg)
・systolic 128.0±23.1 134.4±17.6 0.37
・diastolic 70.1±12.3 77.3±9.0 0.07
Fasting blood sugar (mg/dL) 152.1±39.9 152.4±34.0 0.98
HbA1c (NGSP)% 8.3±1.4 8.0±1.4 0.58
Low-density lipoprotein (mg/dL) 111.8±34.3 107.4±33.6 0.71
High-density lipoprotein (mg/dL) 49.7±11.7 44.3±16.8 0.28
Triglyceride (mg/dL) 161.5±130.4 198.9±164.6 0.48
※OHA: Oral hypoglycemic agent
Table 2. Comparison of the two groups of two-channel (airflow and SpO2) portable monitor findings at baseline 
between patients who did (Group 1) and did not undergo (Group 2) prosthetic mandibular advancement therapy 
Group 1
(n=18)
Group 2
(n=16)
p
Total scoring time (min) 407.7±34.3 409.5±35.5 0.88
Respiratory disturbance index (/h) 17.7±9.8 16.9±13.0 0.82
Apnea episode (times/night) 86.3±70.8 80.3±81.5 0.82
Hypopnea episode (times/night) 35.3±27.9 37.6±30.7 0.82
4% oxygen desaturation episode 
(times/night)
95.6±60.2 105.8±79.7 0.67
4% oxygen desaturation index (/h) 14.0±8.6 15.3±10.8 0.71
Minimum SpO2 (%) 79.8±6.0 81.4±10.6 0.58
Mean SpO2 (%) 94.6±1.8 95.8±1.7 0.053
Baseline With PMA p
Total scoring time (min) 407.7±34.3 383.8±61.8 0.15
Respiratory disturbance index (/h) 17.7±9.8 8.3±7.7 <0.001
Apnea episode (times/night) 86.3±70.8 40.3±49.4 <0.001
Hypopnea Episode (times/night) 35.3±27.9 15.7±10.2 <0.001
4% oxygen desaturation episode 95.6±60.2 53.7±48.5 <0.001
4% oxygen desaturation index (/h) 14.0±8.6 8.6±7.8 0.002
Minimum SpO2 (%) 79.8±6.0 85.7±4.5 <0.001
Mean SpO2 (%) 94.6±1.8 95.9±1.8 0.03
Table 3. Changes in two-channel (airflow and SpO2) portable monitor findings after prosthetic mandibular 
advancement therapy (Group 1; n = 18)
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